Key terms
About JNJ
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest JNJ news
Today
6:47am ET
Hold Rating on Johnson & Johnson Amid Varipulse PFA Catheter Recall and Approval Uncertainties
Yesterday
12:00am ET
Buy Rating Affirmed: Johnson & Johnson’s Bladder Cancer Treatments Poised to Transform Standard of Care
May 07
8:03am ET
Analysts Offer Insights on Healthcare Companies: Pliant Therapeutics (PLRX), Johnson & Johnson (JNJ) and Hims & Hers Health (HIMS)
May 07
5:16am ET
Johnson & Johnson: Navigating Legal Challenges with a Strategic Settlement Outlook
May 07
12:15am ET
Johnson & Johnson (JNJ) Receives a Buy from Cantor Fitzgerald
May 06
4:13pm ET
ShockWave Medical reports Q1 diluted EPS $1.44, consensus 98c
May 06
12:45pm ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
May 06
10:45am ET
Cantor Fitzgerald biotech analysts hold an analyst/industry conference call
May 06
7:55am ET
Cantor Fitzgerald healthcare/pharma analysts analyst/industry conference call
May 06
4:55am ET
Cantor Fitzgerald healthcare/pharma analysts analyst/industry conference call
May 05
2:23pm ET
Johnson & Johnson announces updated results from Phase 1 study of TAR-210
May 05
6:45am ET
Johnson & Johnson’s Strategic Settlement Plan Bolsters Buy Rating
May 03
2:33pm ET
New Prostate Cancer Treatment Data Not Much Help to Johnson & Johnson (NYSE:JNJ)
May 03
12:28pm ET
Johnson & Johnson says Phase 2 Apa-RP study meets primary endpoint
May 03
11:19am ET
Johnson & Johnson announces updated results from Cohort 2 of SunRISe-1 study
May 02
5:36pm ET
Cantor Fitzgerald healthcare/pharma analysts analyst/industry conference call
May 02
11:06am ET
Genmab reports Q1 revenue increased 46% vs. last year
May 02
5:19am ET
Johnson & Johnson’s Strategic Settlement Plan for Ovarian Cancer Talc Claims: Financial Implications and Outlook
May 02
5:16am ET
Hold Rating on Johnson & Johnson Amid Ongoing Talc Litigation Uncertainties and Settlement Efforts
May 01
12:15pm ET
Johnson & Johnson (NYSE:JNJ) Is Paying $6.5B to Settle Lawsuit
May 01
11:45am ET
Johnson & Johnson management to meet with Oppenheimer
May 01
7:12am ET
Johnson & Johnson Announces Major Talc Litigation Settlement Plan
May 01
6:37am ET
J&J says talc plan commits company to pay claimants $6.475B
May 01
6:35am ET
J&J’s LLT proposes to resolve all ovarian cancer talc claims via reorganization
May 01
6:32am ET
J&J’s LLT proposes to resolve all ovarian cancer talc claims via reorganization
May 01
4:55am ET
Johnson & Johnson management to meet with Oppenheimer
Apr 30
10:13am ET
FTC expands patent listing challenges for drugs
Apr 29
10:20am ET
J&J receives positive CHMP opinion recommending approval of Sirturo in MDR TB
Apr 24
11:24pm ET
LLY vs. JNJ: Which Big Pharma Stock Is Better?
Apr 24
4:13pm ET
Cidara Therapeutics reacquires rights to CD388 from Johnson & Johnson for $85M
Apr 24
2:23pm ET
Johnson & Johnson management to meet with Oppenheimer
No recent press releases are available for JNJ
JNJ Financials
Key terms
Ad Feedback
JNJ Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
JNJ Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
